Qiming Weekly | Qiming Venture Partners Portfolio News & Updates Vol. 33, 2025
Celebrating milestone moments with you at Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth documenting. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in celebrating the milestone moments of our portfolio companies.
Funding News
Epicrispr Biotech Closes $60 Million Series B Round Qiming Venture Partners Continues Investment
Clinical-stage innovative drug R&D company Epicrispr Biotech recently announced the completion of a $60 million Series B financing round. Existing investor Qiming Venture Partners participated in this round. The proceeds will primarily support continued clinical development of EPI-003 for functional cure of chronic hepatitis B and EPI-001 for hypercholesterolemia treatment. Additionally, funds will accelerate multiple preclinical programs and ongoing platform development, injecting strong momentum into Epicrispr Biotech's deep cultivation in the epigenetic drug R&D field.
As a leading biotechnology company dedicated to developing next-generation epigenetic regulation technologies for chronic diseases, Epicrispr Biotech consistently stays at the forefront of the industry. The company's proprietary EPIREG™ technology platform leverages precise DNA methylation and histone modification to efficiently, durably, and specifically silence target genes. Compared to traditional gene editing tools that cut DNA, this approach offers chronic disease patients a safer, revolutionary treatment option that effectively circumvents the safety concerns associated with conventional gene editing.
Dr. Baohong Zhang, co-founder and CEO of Epicrispr Biotech, stated: "We are deeply grateful for the trust and support from both new and existing investors. Since our founding, we have remained focused on the R&D and translation of epigenetic regulation technologies, achieving significant progress in just a few short years. We will continue advancing clinical development of our core pipeline to bring safe and effective innovative treatments to patients as soon as possible."
Major Partnerships
01/
UBTECH Secures 250 Million Yuan Humanoid Robot Purchase Order Setting New Global Single-Contract Record
Following its nearly 100 million yuan record-breaking single order in July — the largest ever for a global humanoid robot company — Qiming Venture Partners portfolio company UBTECH (09880.HK) has once again set a new record, signing a 250 million yuan procurement contract for embodied intelligence humanoid robot products and solutions with a prominent domestic enterprise. The contract centers on the Walker S2 humanoid robot, which features an autonomous hot-swappable battery system, with UBTECH set to begin delivery this year. This represents the largest contract in the global humanoid robot sector to date.
According to publicly available statistics, to date, UBTECH's Walker series humanoid robots have secured contracts totaling nearly 400 million yuan (including the nearly 50 million yuan in H1 delivered humanoid robot orders), not counting orders for Tiangong Xingzhe, the full-size research and education humanoid robot jointly launched by UBTECH and the Beijing Humanoid Robot Innovation Center in March.
Currently, UBTECH has partnered with leading enterprises across new energy vehicle manufacturing, 3C manufacturing, and smart logistics, including BYD, Dongfeng Liuzhou Motor, Geely Auto, FAW-Volkswagen Qingdao Branch, Audi-FAW, BAIC Group, Foxconn, and SF Express. Its industrial humanoid robot Walker S series has become the humanoid robot deployed in the most factory training environments worldwide.
02/
Hesai Technology Secures Another Global Exclusive Lidar Order from Motional
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ:HSAI) announced that for two consecutive years it has served as the exclusive near-range lidar supplier for Motional's all-electric IONIQ 5 Robotaxi, continuing to provide core perception support for its autonomous driving fleet. Each vehicle is equipped with four Hesai lidar units. This collaboration not only confirms the long-term, stable strategic partnership between the two parties, but also highlights Hesai Technology's sustained leading market position and technological advantage in the Robotaxi sector.
As a core safety component of autonomous driving, lidar is often described as the "eyes" of a vehicle, ensuring user travel safety and experience. Hesai Technology's lidar not only leads the industry in performance but also excels in data security — achieving the highest ratings in third-party security assessments conducted by internationally authoritative testing and certification bodies TÜV Rheinland and DEKRA. Hesai Technology is the world's first lidar company to simultaneously obtain ISO/SAE 21434 cybersecurity certification, ISO 21448 safety of the intended functionality process certification, and ISO 26262 product functional safety certification, fully demonstrating the company's firm commitment to providing the highest level of safety assurance.
03/
Berry Genomics and Tencent Cloud Join Forces to Launch AI-Driven Life Health Initiative
Recently, Qiming Venture Partners portfolio company Berry Genomics (000710.SZ) formally signed a Strategic Cooperation Agreement with Tencent Cloud, a major player in cloud computing. Upholding the principles of "leveraging strengths, mutual advancement, long-term cooperation, and mutual benefit," the two parties have decided to join forces in depth to jointly explore the boundless possibilities of artificial intelligence in life health, aiming to expand the depth and breadth of cooperation, enhance target benefits for both sides, and embark on a transformative journey at the intersection of life health and cutting-edge technology.
Berry Genomics and Tencent Cloud will conduct AI application technology R&D and project advancement in specialized fields including reproductive health, genetic disease detection, and scientific services, driving the implementation of AI in life health scenarios and the upgrading of the healthcare industry. Through complementary advantages, they will build exemplary demonstration cases within hospital systems, improve the analysis accuracy and processing speed of genetic data, and form a personal user (C-end) genetic medical service system that combines genetic testing services with health management. The partnership aims to become a new traffic gateway for personal health management, consolidating and expanding Berry Genomics' leading position in the genetic testing industry.
04/
Yanyin Technology and Cirkloon Bio Form Strategic Partnership
Recently, Qiming Venture Partners portfolio company Yanyin Technology and Cirkloon Bio formally signed a three-year strategic cooperation agreement. The two parties will use a digital platform as their collaborative foundation to jointly explore the deep application of AI agents in novel RNA drug R&D, aiming to accelerate the development process of innovative therapies and create a new paradigm for intelligent R&D.
Dr. Zephyr Chen, founder and CEO of Yanyin Technology, said: "We are deeply grateful for Cirkloon Bio's trust and partnership. Their global leadership and deep expertise in circular RNA provide an ideal application scenario for our AI technology. Our strategic vision is clear: 'digitalization first, AI empowerment.' Through Yanyin Cloud's ELN and sample management modules, we first help our clients build a data highway. Only on that highway can our powerful AI agents — including AI knowledge bases, AI literature analysis, and AI experiment design agents — truly unlock their potential, extracting insights from massive datasets to empower scientific decision-making. We look forward to working alongside Cirkloon Bio to establish an industry benchmark for AI for Science in RNA therapeutics, accelerating every breakthrough in life sciences."
05/
BioTree Biotech and Southwest Minzu University Form Strategic Partnership
Jointly Advancing Food Science Innovation and Industry Development
Recently, Qiming Venture Partners portfolio company BioTree Biotech announced a strategic partnership with the School of Pharmacy and Food Science at Southwest Minzu University. Guided by the core principles of "resource sharing, complementary strengths, collaborative innovation, and mutual development," the two parties are joining forces to open a new chapter in university-enterprise collaboration and industrial upgrading.
The collaboration will focus on cutting-edge directions in food science, including food nutrition, metabolomics, proteomics, and genomics. By integrating the university's research resources with the company's technical advantages, both parties will jointly tackle key industry challenges and elevate the overall standard of basic and applied food science research. Each side will leverage its respective strengths: Southwest Minzu University's School of Pharmacy and Food Science will provide theoretical foundations and research direction through its deep disciplinary heritage and talent pool, while BioTree Biotech will contribute its professional capabilities in omics technologies, offering advanced technical support and experimental platform guarantees for research projects. Additionally, both parties plan comprehensive cooperation in key technology breakthroughs, joint talent cultivation, and shared research platform development — helping Southwest Minzu University further strengthen its disciplinary construction and cultivate more high-caliber professionals aligned with industry needs.
R&D Progress
01/
Zai Lab Announces Tivdak Approved in Hong Kong for
Recurrent or Metastatic Cervical Cancer
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced that the Hong Kong Department of Health has approved TIVDAK® (tisotumab vedotin) for the treatment of adult patients with recurrent or metastatic cervical cancer who have experienced disease progression during or after chemotherapy.
Zhu Tong, Chief Commercial Officer of Zai Lab Greater China, stated: "The approval of tisotumab vedotin marks an important milestone for Zai Lab, further strengthening our product portfolio in women's health across Greater China. Treatment options are very limited for patients with recurrent or metastatic cervical cancer following initial therapy. As the first antibody-drug conjugate (ADC) approved for cervical cancer, tisotumab vedotin offers clinically meaningful survival benefits. Leveraging the well-established commercial team we built for Zejula in Hong Kong, we can ensure that tisotumab vedotin reaches patients as quickly as possible."
02/
Belief BioMed Completes First Dosing in DMD Gene Therapy
Registration Clinical Study
Recently, Qiming Venture Partners portfolio company Belief BioMed announced that its self-developed and manufactured BBM-D101 injection has completed first-patient dosing in its registration clinical study (CTR20252461), conducted under the leadership of Dr. Dai Yi, Director of the Neurology Department at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
This open-label, single-dose registration study aims to evaluate the safety and efficacy of intravenous infusion of BBM-D101 injection in boys aged 4–9 with Duchenne muscular dystrophy (DMD). The BBM-D101 injection utilizes a proprietary engineered capsule with expected higher muscle tissue transduction efficiency. Its dosing is lower than comparable recombinant adeno-associated virus (rAAV) gene therapy products already approved abroad, with the expectation of favorable safety. Previously, the BBM-D101 injection initiated an investigator-initiated trial (IIT) in July 2024, and has since completed dosing in six male subjects, yielding promising safety and efficacy data.
03/
Zenitar Announces First Patient Enrollment in Both
Treatment and Control Arms of Pivotal Phase 3 Trial for Purinostat Mesylate
Recently, Qiming Venture Partners portfolio company Zenitar announced that its self-developed Purinostat Mesylate (PM) injection for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has completed first-patient enrollment in both the treatment and control arms of its pivotal Phase 3 clinical trial. The trial is led by Professor Niu Ting of the Department of Hematology at West China Hospital, Sichuan University, and Professor Zhao Weili of Shanghai Ruijin Hospital, marking another significant milestone step for Zenitar.
Purinostat Mesylate is a novel HDAC 1/2b highly selective inhibitor and the only HDAC inhibitor approved by regulators for the treatment of B-cell lymphoma, T-cell lymphoma, and solid tumors. Its mechanism of action encompasses not only epigenetic regulation-mediated anti-tumor effects, but also immune activation and induction of immune memory, thereby achieving synergistic anti-tumor effects.
04/
Raymon Bio PEG Hydrogel Research Published
in Leading International Journal Advanced Materials
Recently, a team from Qiming Venture Partners portfolio company Raymon Bio collaborated with researchers from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences to develop an innovative organic afterglow luminescence probe technology. By precisely modulating oxygen quenching rates (kq), the probe triggers a visible long-afterglow signal the instant hydrogel formation occurs. This technology represents a revolutionary breakthrough in real-time visualization of hydrogel formation, ushering in a new era of precision monitoring for medical applications. The related paper was published in Advanced Materials.
Dr. Zhang Zhanpeng, Vice General Manager and Chief Technology Officer of Raymon Bio, stated: "We are working to build an internationally leading medical hydrogel technology platform, providing foundational technical support for precision medicine. With conventional hydrogel technology, physicians cannot confirm whether the gel has solidified in the correct position, creating clinical risks of gel displacement and functional failure. Oxygen-responsive afterglow probe technology transforms hydrogel formation in vivo from 'unknowable' to 'real-time visible' — a milestone breakthrough for precision medicine."
Product Launches
01/
Shenzhen HugeMed Disposable Electronic Choledochoscope
Approved by National Medical Products Administration
Recently, Qiming Venture Partners portfolio company Shenzhen HugeMed announced that its disposable electronic choledochoscope has been approved by the National Medical Products Administration.
The product's handle buttons can be customized via the MS-8 image processor, offering users greater convenience. The soft insertion tube tip achieves 210° active bending and passive bending, ensuring flexible navigation through tortuous, narrow passages while reducing the risk of injury. Its high-definition CMOS camera paired with two LED cold light sources improves visualization. Insertion tube markings help physicians assess advancement distance, contributing to enhanced surgical precision.
02/
Shukun Technology's Coronary CTA and Plaque Analysis AI Diagnostic System
Receives FDA 510(k) Clearance
Recently, Qiming Venture Partners portfolio company Shukun Technology announced that its self-developed coronary CTA and plaque analysis AI diagnostic system has officially received FDA 510(k) clearance.
This marks Shukun Technology's third FDA certificate in the United States, and establishes the company as the only medical AI enterprise globally to possess full-pipeline AI-assisted diagnostic capabilities spanning cardiac, carotid, and intracranial applications — all with FDA market access.
From image reconstruction and diagnosis to precise plaque analysis and report generation, the system operates entirely without human intervention. It delivers not only conclusions but also clear visualization of plaque location and composition (lipid/fibrolipid/fibrous/calcified), giving physicians confidence to understand and adopt its findings — truly integrating into clinical workflows.
03/
Sanyou Medical's Zeus Spinal Internal Fixation System International Brand
Receives FDA 510(k) Clearance
Recently, Qiming Venture Partners portfolio company Sanyou Medical (688085.SH) announced that its innovative product, the Zeus spinal internal fixation system's international brand Jazz Spinal System ("JSS"), has successfully passed FDA 510(k) review, completed its upgrade, and received registration clearance. This marks continued breakthroughs in market access qualifications for Sanyou Medical's self-developed spinal implants in North America's premium market, and accelerates the company's overseas strategic expansion.
The core of this certification upgrade lies in JSS system's deep optimization based on clinical needs and customer feedback — building upon the original Jazz Spinal System, it dramatically expanded the specification range of system screws, offering more product options for patients of different body types in European and American markets, further addressing needs including spinal fusion, spondylolisthesis, fractures, and complex spinal deformity correction; covering more spinal disease treatment scenarios and surgical modalities to provide more precise solutions for physicians and patients worldwide.
Technology Strength
01/
WeRide's First Batch of Robotaxi GXR
Arrives in Singapore and Begins Testing
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ:WRD) announced that its first batch of Robotaxi GXR vehicles has arrived in Singapore and begun testing — the first deployment of this autonomous driving model in Southeast Asia.
These Robotaxi GXR vehicles are currently undergoing simulated road testing at the Nanyang Technological University's Centre of Excellence for Testing and Research of Autonomous Vehicles (CETRAN), evaluating vehicle performance and safety under Singapore's public road conditions in preparation for M1 certification. Upon approval, the vehicles are expected to deploy on designated public roads by the end of 2025, operated in partnership with a leading regional mobility service provider, laying groundwork for future large-scale commercialization. Each Robotaxi GXR can accommodate up to five passengers.
Tony Han, WeRide's founder and CEO, stated: "The deployment of our Robotaxi GXR in Singapore paves the way for launching more autonomous driving services in the region. Building on WeRide's leading technical capabilities and the massive real-world data we've accumulated in comparable urban environments globally, we have optimized deployment for Singapore's road conditions. Safety remains WeRide's top priority. Through rigorous testing processes and deep collaboration with industry partners, we are establishing a solid foundation for the commercial rollout of autonomous driving services in Southeast Asia."
02/
WeRide's New Mass-Produced Robotaxi GXR Launches
24-Hour Fully Driverless Commercial Operations in Huangpu District, Guangzhou
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ:WRD) announced that its new mass-produced autonomous mobility service vehicle (Robotaxi) GXR has officially launched 24-hour fully driverless commercial operations in Huangpu District, Guangzhou.
Users can download the "WeRide Go" app to view the operating zone and select any pickup and drop-off points within the zone to place orders and experience "anytime, anywhere, comfortable and convenient" future mobility. This also represents the industry's first point-to-point autonomous driving commercial mobility service in the core urban area of a megacity, fully demonstrating WeRide's leading position, operational experience, and deep accumulation in the global Robotaxi industry.
From the GXR new model launch in October 2024, to rapidly completing road testing, vehicle certification, operating licenses, and other procedures, and then efficiently transitioning from in-vehicle attendant commercial operations to fully driverless commercial operations — WeRide accomplished all this in just 11 months, once again demonstrating to the industry the "WeRide speed" of driving fully driverless Robotaxi commercial deployment.
03/
Free-Weight Full-Chain Self-Developed Music Model
YinChao Music Passes AI Service Filing
Recently, Qiming Venture Partners portfolio company Free-Weight's fully self-developed music large model — "YinChao Music" — has successfully passed the filing for generative AI services by China's Cyberspace Administration (filing number: Shanghai-YinChaoYinYue-202507160059). This marks that the model has met national requirements in compliance, security, and reliability. YinChao Music's emergence breaks the previous scarcity of consumer-facing commercial-grade music models in China, and establishes a solid foundation for Free-Weight's deep cultivation in the vertical music domain.
Free-Weight's R&D team abandoned traditional approaches, pioneering an AR+NAR hybrid architecture. This leading design enables the model to combine excellent long-term structural coherence with fine-grained local detail generation, effectively capturing global dynamic changes in music and reconstructing them with high fidelity.
To pursue immersive music generation to the extreme, the team also independently developed a diffusion transformer model (DiT) that can directly perform joint modeling on stereo signals. Leveraging its unique attention mechanism, this model can precisely capture and synchronize subtle phase differences, intensity differences, and time delays between left and right channels. Consequently, the model generates not flat monophonic expansion but stereo audio with authentic, natural spatial perception — constructing a believable sound field with width, depth, and positional sense for listeners, delivering a truly immersive auditory experience.
04/
Mofan Power-Leaded Turbomachinery
Waste Heat Recovery Technical Specification Group Standard Successfully Published and Implemented
Recently, the group standard Technical Specification for Waste Heat Recovery of Turbomachinery (standard number: T/CIET 1593—2025), led by Qiming Venture Partners portfolio company Mofan Power, was officially published and implemented.
The group standard document specifies requirements for turbomachinery waste heat recovery technology covering principles and processes, guaranteed values, product safety, technology, system equipment, inspection and testing, packaging, transportation, and storage. Addressing the current gap in China's turbomachinery industry standards, this group standard promotes healthy development of the turbomachinery sector.
05/
Gan & Lee Pharmaceuticals Debuts at African Pharmaceutical Exhibition
Pharmaconex 2025
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) showcased its insulin product portfolio, companion delivery devices, and cutting-edge innovation pipeline at the African pharmaceutical exhibition Pharmaconex 2025.
During the exhibition, Gan & Lee Pharmaceuticals unveiled the latest research findings on its two pipeline drugs: bofanglutide (GZR18), an investigational innovative GLP-1 drug, and GZR4, a once-weekly long-acting insulin. Together, these aim to provide patients worldwide with a multi-layered solution spanning from foundational treatment to complex glucose management. Through its distinctive framework of "independent R&D + full-chain deployment + localized partnerships," Gan & Lee presented a comprehensive collaboration strategy for diabetes care to a global audience.
06/
Berry Genomics Earns DCMM Level 2 Certification
Recently, the China Electronics Industry Association officially released the latest list of certified organizations under the Data Management Capability Maturity Model (DCMM). Qiming Venture Partners portfolio company Berry Genomics (000710.SZ) successfully attained DCMM Level 2 certification, becoming one of the first companies in the genomics sector to receive this national standard accreditation.
Achieving DCMM Level 2 certification means Berry Genomics has established a robust data management system with the capability to systematically implement data quality control, security governance, and lifecycle management. The company has also put in place preliminary mechanisms for quantifying data value, laying a solid foundation for high-quality growth.
07/
Antai Micro Precision Supports China's First Robot-Assisted Microsurgical Free Tissue Flap Reconstruction for Maxillofacial Region
Recently, under the assistance of Kai, a microsurgical robot system developed by Qiming Venture Partners portfolio company Antai Micro Precision, a team led by Vice Director Cai Zhigang and Director Shan Xiaofeng from the Department of Oral and Maxillofacial Surgery at Peking University School of Stomatology completed China's first maxillofacial vascularized free tissue flap reconstruction assisted by a microsurgical robot. The procedure demonstrated the feasibility and standardization potential of performing complex microsurgical reconstruction in deep head and neck regions with confined surgical fields.
This case achieved radical tumor resection alongside precise functional repair and reconstruction, further validating Kai's clinical value in challenging maxillofacial reconstructions.
08/
Frontage Pharma Secures Drug Manufacturing License and CNAS Accreditation, Fully Empowering Drug R&D and Commercialization
Recently, Frontage Pharmaceutical, a subsidiary of Qiming Venture Partners portfolio company Frontage Pharma, successfully obtained a Drug Manufacturing License (Type C) and CNAS laboratory accreditation. The dual qualifications signify that Frontage Pharma's quality management system, manufacturing operations, and analytical testing capabilities have all met authoritative standards, enabling the company to further provide clients with high-quality CMC services from clinical through commercial stages.
The approval of the Drug Manufacturing License (Type C) marks Frontage Pharma's qualification for commercial production of marketed drugs. The company has successfully extended its value chain from "R&D services" to "R&D + manufacturing," opening up broader space for business development.
Frontage Pharmaceutical's analytical testing center obtaining CNAS accreditation demonstrates that its quality management and technical capabilities comply with international standards. This enables the provision of credible testing data for projects, significantly enhancing the reliability and regulatory compliance of drug application materials and accelerating the registration process.
Corporate Honors
01/
Multiple Qiming Venture Partners Portfolio Companies Named to 2025 Shanghai Specialized, Sophisticated, and Innovative SME List (Second Batch)
Recently, the 2025 Shanghai Specialized, Sophisticated, and Innovative SME List and Innovative SME List (Second Batch) were announced. These two initiatives aim to enhance the innovation capabilities and specialization of SMEs, promote high-quality SME development, and contribute to the advancement of industrial infrastructure and modernization of industrial chains.
Qiming Venture Partners portfolio companies Infinigence AI, Eigencomm, Insilico Medicine, Stackless Data, Fushoukang, and Qianmai Medical were named to the 2025 Shanghai Specialized, Sophisticated, and Innovative SME List (Second Batch); Houmo AI, Yanyin Technology, and Insilico Medicine were named to the 2025 Shanghai Innovative SME List (Second Batch).
02/
Seven Qiming Venture Partners Portfolio Companies Selected for QbitAI Institute's 2025H1 AI 100 Product Rankings
Recently, QbitAI Institute released the 2025H1 AI 100 Product Rankings. The selection comprises two lists — flagship products and innovative products — with the former representing the current leadership tier and the latter identifying future market contenders. Together, the two lists paint a more three-dimensional and authentic picture of the AI product landscape, providing reference points for industry participants and observers.
Qiming Venture Partners portfolio companies Zhipu AI, StepFun, Zhihu (NYSE: ZH, 02390.HK), and Meitu (01357.HK) were named to the 2025H1 AI 100 Flagship Product List; Zhipu AI, DeepWise, Shengshu Technology, and Mafengwo were named to the 2025H1 AI 100 Innovative Product List.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Funding and Updates Vol. 32, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.